Bringing SOT 2020 to you

Having missed the opportunity to share developments with colleagues at SOT 2020 we’ve prepared a digital version of our poster presentation.

Get your poster presentation booklet and accompanying audio

Microphysiological System for Studying Fatty Liver Disease and Its Impact on Drug-Induced Liver Injury.

Overview: As a result of the increased prevalence of diabetes, obesity and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed countries (1). NAFLD is a spectrum of pathologies ranging from benign hepatic steatosis through to non-alcoholic steatohepatitis (NASH), which can ultimately lead to cirrhosis and liver cancer. There are currently no FDA approved drugs for the treatment of NAFLD/NASH and there is a clear requirement for better models to understand this disease.

Tomasz Kostrzewski, Alina Miedzik, David Hughes
CN Bio, Cambridge, UK

Sophie Reagen, Abhishek Srivvastava, Dominic Williams
AstraZeneca, Cambridge, UK

COMPANY HEAD OFFICE INFORMATION:

332 Cambridge Science Park
Milton Road
Cambridge
CB4 0WN

+44 (0) 1223 737941
enquiries@cn-bio.com

FOR PRODUCT, SERVICES AND MARKETING ENQUIRIES:

+44 (0) 1223 737941
enquiries@cn-bio.com

CN BIO INNOVATIONS LIMITED REGISTERED OFFICE:

30 Upper High Street, Thame,
Oxfordshire, OX9 3EZ.

Registered No. 06517359.
VAT No. 978184563